

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Nogapendekin alfa inbakicept with intravesical BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG [ID6582]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Stakeholders at consultation raised the following potential equalities issues:

- Non-muscle-invasive bladder cancer is more common in people over the age of 75, who may be unable to, or prefer not to have, a radical cystectomy.
- Non-muscle-invasive bladder cancer affects more men than in women (3:1 ratio) although women are more likely to be diagnosed at a later stage
- There is potential inequality of access to nogapendekin alfa inbakicept with intravesical BCG for people with non-muscle-invasive bladder cancer living in rural areas or near smaller hospitals.
- Socioeconomic factors could also result in inequality of access to nogapendekin alfa inbakicept.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

- The committee will evaluate the technology within the age group included in its anticipated marketing authorisation wording.
- The committee will consider the potential equality issues raised during the appraisal process and whether its recommendations could have a different impact on people protected by the equality legislation.
- Issues related to access to services, such as geographical location, cannot be addressed in a technology appraisal.
- The committee will consider evidence about health inequalities where it is presented.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

None

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

None

Approved by Principal Technical Adviser (name): Elizabeth Bell

Date: 20/10/2025